IRRAS Croissance future

Future contrôle des critères 2/6

IRRAS devrait augmenter ses bénéfices et ses revenus de 38.8% et de 63% par an respectivement, tandis que le BPA devrait croître de diminuer de 104.4% par an.

Informations clés

38.8%

Taux de croissance des bénéfices

-104.4%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	36.9%
Taux de croissance des recettes	63.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	24 Jul 2023

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

OM:IRRAS - Estimations futures des analystes et données financières antérieures (SEK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	320	N/A	N/A	N/A	1
12/31/2024	195	-108	-141	-127	1
12/31/2023	116	-150	-170	-162	2
6/30/2023	43	-196	-195	-192	N/A
3/31/2023	43	-193	-197	-193	N/A
12/31/2022	40	-167	-179	-176	N/A
9/30/2022	37	-164	-160	-157	N/A
6/30/2022	32	-141	-133	-129	N/A
3/31/2022	27	-131	-134	-129	N/A
12/31/2021	22	-136	-138	-131	N/A
9/30/2021	18	-131	-131	-123	N/A
6/30/2021	14	-135	-134	-125	N/A
3/31/2021	10	-140	-139	-129	N/A
12/31/2020	7	-136	-141	-133	N/A
9/30/2020	8	-134	-151	-144	N/A
6/30/2020	7	-139	-159	-152	N/A
3/31/2020	7	-147	-166	-152	N/A
12/31/2019	5	-151	-169	-154	N/A
9/30/2019	2	-165	-159	-138	N/A
6/30/2019	1	-171	-146	-125	N/A
3/31/2019	0	-160	-130	-116	N/A
12/31/2018	6	-139	-112	-97	N/A
9/30/2018	7	-112	-103	-95	N/A
6/30/2018	18	-78	-90	-82	N/A
3/31/2018	18	-67	-78	-68	N/A
12/31/2017	12	-61	-65	-54	N/A
9/30/2017	11	-48	-53	-35	N/A
12/31/2016	N/A	-32	N/A	-18	N/A
12/31/2015	N/A	-13	N/A	-11	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: IRRAS devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: IRRAS devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: IRRAS devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de IRRAS ( 63% par an) devrait croître plus rapidement que le marché Swedish ( 0% par an).

Croissance élevée des revenus: Le chiffre d'affaires de IRRAS ( 63% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de IRRAS devrait être élevé dans 3 ans

IRRAS Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Price target increased by 69% to kr5.00

Consensus revenue estimates decrease by 25%

Price target increased to kr5.00

IRRAS AB Provides Revenue Guidance for the Year 2022

Price target decreased to kr7.00

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00

New 90-day high: kr6.98

Analysts increase revenue estimates to kr27.5m

First half earnings released

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance